(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 695.9MM | +4% |
Gross Profit | - | - |
Cost Of Revenue | - | - |
Operating Income | 77.2MM | +11% |
Operating Expenses | - | - |
Net Income | 78.6MM | - |
R&D | 49.6MM | -6% |
G&A | 256.7MM | +3% |
Amortization | 89.6MM | -1% |
Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
WALTHAM, Mass., June 01, 2023--Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis.
WALTHAM, Mass., May 24, 2023--Revvity, Inc. (NYSE: RVTY) will present at the 44th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. PT at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA.
A long-established name has disappeared from the market, replaced by a slimmed-down company with a new name
WALTHAM, Mass., May 18, 2023--Revvity, Inc. (NYSE: RVTY), today announced a new license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for the technology underlying its Pin-point™ base editing system, a next-generation modular gene editing platform with a strong safety profile.
Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.
PerkinElmer (PKI) delivered earnings and revenue surprises of 2.02% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass., May 11, 2023--Revvity, Inc. (NYSE: PKI), today reported financial results for the first quarter ended April 2, 2023.
Revvity (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Waters (WAT) delivered earnings and revenue surprises of -4.23% and 1.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass., May 09, 2023--Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was previously affiliated with PerkinElmer, Inc.